Received Mar 11, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | 1 | Y009348 | — |
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | 2 | Y017205 | — |
No additional AE/; Patient received a dose of PROQUAD in September and another dose in February. No reported signs or symptoms of adverse effects. Permission to contact HCP was given. No additional AE/no PQC; Patient received a dose of PROQUAD in September and another dose in February. No reported signs or symptoms of adverse effects. Permission to contact HCP was given. No additional AE/no PQC; This spontaneous report was received from a medical assistant referring to a patient of unknown age and gender. The patient's medical history, historical drugs, past drug reactions or allergies, concurrent conditions, and concomitant drugs were not reported. On an unknown date in September 2024, the patient was vaccinated with the first dose of Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD) injection (lot#: y009348, expiration date: 11-NOV-2025; strength, dose, and route of administration were not reported) for prophylaxis. On 25-FEB-2025, the patient was vaccinated with the second dose of Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD) injection (lot#: y017205, expiration date: 13-APR-2026; strength, dose, and route of administration were not reported) for prophylaxis (inappropriate age at vaccine administration and inappropriate schedule of vaccine administered). . No reported signs or symptoms of adverse effects.
Sterile Diluent